EKF Diagnostics, the point of care diagnostics company, announced that Interim results to June 2011 (with pro-forma comparative results) showed sales of £7.4 million (2010: £6.0 million) and adjusted EBITDA of £210,000 (2010: £(51,000)). The pre-tax loss was £1.55 million (2010: £(302,000)), actual not pro-forma.
The company reported that the period was impacted by the costs involved in moving from an essentially owner-managed structure and culture to one that is more reflective of the demands of a higher-growth/higher governance led environment. Gross margin was 64% (2010: 58%). Period end net cash was £2.8 million.
The EKF share price has increased by 3% over the past year.
EKF Diagnostic Holdings Plc is currently graded C by LCF Research. To learn more, follow the link.
Disclaimer:
This note was prepared by LCF Research Limited using information provided by the subject company’s management or publically available news sources. No representations are made nor warranties given (express or implied) in relation to accuracy and completeness. This document is not an invitation to invest in the subject company and does not purport to contain all the necessary information that a prospective investor might require. LCF Research Limited recommends prospective investors to conduct their own thorough independent analysis of the subject company and the information contained in this note or referred to above.
EKF Diagnostics Holdings Plc, formerly International Brand Licensing plc, designs, develops, manufactures and sells diagnostic instruments, reagents and certain ancillary products. The Company is focused within the In-Vitro Diagnostic devices (IVD) market place. Other services include the servicing and distribution of other Company products under separate distribution agreements. The Company operates in Germany, United Kingdom, Ireland, Poland and Russia. On July 2, 2010, the Company acquired 100% interest of EKF-diagnostic Gmbh. On October 4, 2010, the Company acquired 100% of the share capital of Quotient Diagnostics Limited. On December 2, 2010, the Company acquired 100% of the share capital of Argutus Medical Limited. During 2010, the Company discontinued its licensing business and disposed of its portfolio of sports and lifestyle brands. In March 2012, the Company sold International Brand Licensing AG (IBL AG). more »
